SecProbe.io

CORRESP
1
filename1.htm

1(213) 683-6188

jonathanko@paulhastings.com

July
18, 2024

VIA EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

Office
of Real Estate & Construction

100 F Street, NE

Washington, D.C. 20549

Attention: Pearlyne Paulemon

Pam
Howell

Frank
Knapp

Jennifer
Monick

 Re: Vine
Hill Capital Investment Corp.

    Draft
Registration Statement on Form S-1

    Submitted June 11, 2024

    CIK No. 0002025396

Ladies
and Gentlemen:

On
behalf of Vine Hill Capital Investment Corp., a Cayman Islands exempted company (the “Company,” “we,”
“us,” or “our”), reference is made to the letter dated July 15, 2024 (the “Comment
Letter”) from the staff (the “Staff”) of the Division of Corporation Finance of the Securities
and Exchange Commission (the “Commission”) regarding the above-referenced Draft Registration Statement on Form
S-1, confidentially submitted with the Commission on June 11, 2024 (the “Draft Registration Statement”).

Separately
today, the Company has publicly filed with the Commission the Registration Statement on Form S-1 (“Form S-1”)
through EDGAR in response to the Staff’s comments.

For
your convenience, each of the Staff’s comments contained in the Comment Letter is duplicated below in bold and is followed by the
Company’s responses thereto (including page references to the Form S-1, when applicable). Capitalized terms used but not otherwise
defined herein have the meanings ascribed to such terms in the Form S-1.

Draft
Registration Statement on Form S-1 submitted June 11, 2024

Cover
Page

 1. Please
clearly disclose the “certain conditions as further described herein” relating to the redemption of public shareholders in
connection with the liquidation of the company. We are unable to locate disclosure elsewhere in the prospectus regarding these certain
conditions.

In
response to the Staff’s comment, we have revised the cover page of the Form S-1 to remove the reference to conditions relating
to the redemption of public shareholders in connection with the liquidation of the company as well as provided a cross-reference to the
appropriate section in the Form S-1.

Paul
Hastings LLP | 515 South Flower Street | Twenty-Fifth Floor | Los Angeles, CA 90071

t:
+1.213.683.6000 | www.paulhastings.com

Securities and Exchange Commission

July 18, 2024

Page 2

 2. Please
                                            clearly disclose any limitations upon redemptions, as required by Item 1602(a)(2) of Regulation
                                            S-K. For example, we note the disclosure on page 27 regarding the limitation on redemption
                                            of shareholders holding more than 15% of the shares sold in this offering if a shareholder
                                            vote is held, and the limitation on redemptions that would cause net tangible assets to be
                                            less than $5,000,001, as referenced on page 26.

In
response to the Staff’s comment, we have revised the cover page of the Form S-1.

 3. Please
                                            revise the disclosure regarding dilution relating to the founders shares to also disclose
                                            whether the anti-dilution adjustment to the founders shares in connection with the initial
                                            business combination may result in material dilution of purchasers’ equity interests. See
                                            Item 1602(a)(3) of Regulation S-K.

In
response to the Staff’s comment, we have revised the cover page of the Form S-1.

 4. When
                                            discussing the amount of compensation received or to be received, as required by Item 1602(a)(3)
                                            of Regulation S-K, please include the repayment of loans.

In
response to the Staff’s comment, we have revised the cover page of the Form S-1.

 5. When
                                            discussing the class B ordinary shares, please revise to clarify that the class B ordinary
                                            shares will have the right to vote on the appointment or removal of directors.

In
response to the Staff’s comment, we have revised the cover page of the Form S-1.

 6. Please
                                            revise the compensation disclosure to also include the amount of compensation to be paid
                                            to your CFO Daniel Zlotnitsky, and Executive Chairman Nominee Dean Seavers, as referenced
                                            on page 30. See Item 1602(a)(3) of Regulation S-K.

In
response to the Staff’s comment, we have revised the cover page of the Form S-1.

 7. Please
                                            provide a cross-reference to all the sections in the prospectus for disclosures related to
                                            each of compensation, dilution, and material conflicts of interest, as required by Item 1602(a)(3),
                                            (4), and (5) of Regulation S-K.

In
response to the Staff’s comment, we have revised the cover page of the Form S-1.

 Securities and Exchange Commission

July 18, 2024

Page 3

Competitive
Strengths, page 3

 8. Please
                                            expand your disclosure to clearly identify any special purpose acquisition company business
                                            combinations in which your management team has participated. For each SPAC, clearly disclose
                                            any extensions and redemption levels in connection with any extension and/or business combination.
                                            For those SPACs that have completed a de-SPAC transaction, disclose the current trading prices.
                                            See Item 1603(a)(3) of Regulation S-K.

In
response to the Staff’s comment, we have revised the Form S-1 on pages 5 and 6.

 9. We
                                            note that Kevin Charlton is designated as your special advisor. Please disclose the role
                                            of your advisor and any related compensation they will receive in connection with your initial
                                            public offering or your initial business combination.

In
response to the Staff’s comment, we have revised the Form S-1 on page 5.

Initial
Business Combination, page 6

 10. Please
                                            disclose whether security holders will have voting or redemption rights with respect to an
                                            extension to 27 months. In addition, please disclose your plans if you do not consummate
                                            a de-SPAC transaction within 24 months, or 27 months if you have entered into a definitive
                                            agreement for an initial business combination, including whether you expect to extend the
                                            time period, whether there are any limitations on the number of extensions, including the
                                            number of times, and the consequences to the SPAC sponsor of not completing an extension
                                            of this time period. See Item 1602(b)(4) of Regulation S-K.

In
response to the Staff’s comment, we have revised the Form S-1 on page 8.

 11. We
                                            note your disclosure that you may need to obtain additional financing for working capital
                                            needs and transaction costs in connection with the search and completion of the initial business
                                            combination, to complete an initial business combination, or because you become obligated
                                            to redeem a significant number of your public shares. Please describe how additional financings
                                            may impact unaffiliated security holders. See Item 1602(b)(5) of Regulation S-K.

In
response to the Staff’s comment, we have revised the Form S-1 on pages 9, 12, 94 and 103.

Our
Sponsor, page 9

 12. Please
                                            revise the table on page 9 to also include the compensation to be paid to your CFO Daniel
                                            Zlotnitsky, and Executive Chairman Nominee Dean Seavers. See Items 1602(b)(6) and Item 1603(a)(6)
                                            of Regulation S-K.

In
response to the Staff’s comment, we have revised the table on page 11 of the Form S-1.

 13. Please
                                            revise the table disclosing the nature and amount of compensation received or to be received
                                            to include loan reimbursements, the anti-dilution adjustment of the founder shares, and repayment
                                            of out-of-pocket expenses. Also describe the extent to which this compensation and securities
                                            issuance, as well as the private placement warrants which may be exercised on a cashless
                                            basis, may result in a material dilution of the purchasers’ equity interests. See Items
                                            1602(b)(6) and 1603(a)(6) of Regulation S-K.

In
response to the Staff’s comment, we have revised the table on page 12 of the Form S-1.

 Securities and Exchange Commission

July 18, 2024

Page 4

 14. Please
                                            clarify the exception to transfer restrictions by virtue of the sponsor’s LLC agreement.

In
response to the Staff’s comment, we have revised the table on page 13 of the Form S-1.

 15. Please
                                            revise the disclosure on page 10 to also disclose the lock-up agreement with the underwriter,
                                            as discussed on page 171. See Item 1603(a)(9) of Regulation S-K.

In
response to the Staff’s comment, we have revised the Form S-1 on pages 13 and 14.

Conflicts
of Interest, page 31

 16. When
                                            discussing the conflicts of interest of the sponsor and management team from owning securities
                                            in the company, please revise to clearly disclose the nominal price paid for the securities
                                            and the conflict of interest in determining whether to pursue a de-SPAC transaction. In addition,
                                            please add disclosure of the conflicts of interest relating to the compensation, repayment
                                            of loans, and reimbursements of expenses that will be paid to officers and directors affiliated
                                            with the sponsor upon completion of a de-SPAC transaction. Please also disclose the potential
                                            conflicts of interest due to the potential payment of finder’s fees, advisory fees, consulting
                                            fees, or success fees for any services rendered for completion of the initial business combination,
                                            as referenced on page 30. Lastly, please disclose the potential conflicts of interest arising
                                            from the ability to complete a de-SPAC transaction with an entity affiliated with your sponsor,
                                            officers or directors, as disclosed on page 8. See Item 1602(b)(7) of Regulation S-K.

In
response to the Staff’s comment, we have revised the Form S-1 on pages 35 and 36.

Risk
Factors, page 39

 17. With
                                            a view toward disclosure, please tell us whether your sponsor is, is controlled by, has any
                                            members who are, or has substantial ties with, a non-U.S. person. Also revise your filing
                                            to include risk factor disclosure that addresses how this fact could impact your ability
                                            to complete your initial business combination. For instance, discuss the risk to investors
                                            that you may not be able to complete an initial business combination with a target company
                                            should the transaction be subject to review by a U.S. government entity, such as the Committee
                                            on Foreign Investment in the United States (CFIUS), or ultimately prohibited. Disclose that
                                            as a result, the pool of potential targets with which you could complete an initial business
                                            combination may be limited. Further, disclose that the time necessary for government review
                                            of the transaction or a decision to prohibit the transaction could prevent you from completing
                                            an initial business combination and require you to liquidate. Disclose the consequences of
                                            liquidation to investors, such as the losses of the investment opportunity in a target company,
                                            any price appreciation in the combined company, and the warrants, which would expire worthless.

In
response to the Staff’s comment, the Company advises the Staff that the sponsor has only one member who is a non-U.S. person. Such
member owns less than 3% of the economic interests in the sponsor and has no control over the management of the sponsor. The Company
believes that such member’s ownership interest in the sponsor does not present a material risk to the Company’s ability to
consummate an initial business combination and, therefore, such additional risk factor disclosure would not be appropriate in light of
such member’s nominal interest in the sponsor.

Securities and Exchange Commission

July 18, 2024

Page 5

 18. We
                                            note your disclosure beginning on page 63 that the assets in your trust account will be securities,
                                            including U.S. Government securities or shares of money market funds registered under the
                                            Investment Company Act and regulated pursuant to rule 2a-7 of that Act. Please revise to
                                            include disclosure with respect to the consequences to investors if you are required to wind
                                            down your operations as a result of this status, such as the losses of the investment opportunity
                                            in a target company, any price appreciation in the combined company, and any warrants, which
                                            would expire worthless. Please confirm that if your facts and circumstances change over time,
                                            you will update your disclosure to reflect how those changes impact the risk that you may
                                            be considered to be operating as an unregistered investment company.

In
response to the Staff’s comment, we have revised the Form S-1 on page 69.

Management,
page 123

 19. We
                                            note your disclosure on page 22 stating that, in the event your initial shareholders, directors,
                                            officers, or their affiliates were to purchase sha